



Respiratory
Effectiveness
Group

ADVANCES

in Real-life Respiratory Research

The Respiratory Effectiveness Group Newsletter
ISSUE FEBRUARY 2023



◆ page 04
REG
TEAM
UPDATE

◆ page 05
REG WORKING
GROUPS:
PRELIMINARY
SCIENTIFIC
PROGRAMME 2023

◆ page 09
WORKING
GROUP UPDATE

www.regresearchnetwork.org





THE RESPIRATORY EFFECTIVENESS GROUP NEWSLETTER ISSUE FEBRUARY 2023

THE REG BOARD OF DIRECTORS

Walter G Canonica
President

Marc Miravittles
President Elect

Sinthia Bosnic-Anticevich
Past President

Nikos Papadopoulos
Past President

Dermot Ryan
Vice President for Finances and
Supporter Relationships

Nicolas Roche
Vice President for Methodology

Antonio Anzueto
Vice President for Internal
Organisation

Omar Usmani
Vice President for Scientific Outputs

Alan Kaplan
Vice President for Events

Joan B Soriano

OVERSIGHT COMMITTEE

Nick May

Trevor Lambert

Keith Allan

CEO AND SUPPORTER LIAISON

Michael Walker

SCIENTIFIC RESEARCHERS

Graham Lough

Valeria Perugini

FINANCIAL MANAGEMENT

Victoria Cooper

Red Shoes Accounting

CONTENTS



3

EDITORIAL

Giorgio Walter Canonica
REG President

4

REG TEAM UPDATE

Michael Walker
REG CEO

5

REG SUMMIT 2023:

PRELIMINARY SCIENTIFIC
PROGRAMME 2023

9

WORKING GROUPS UPDATE

11

WHAT REG MEANS TO ME

13

ISAR UPDATE

15

ACKNOWLEDGEMENTS



Respiratory
Effectiveness
Group

 enquiries@regresearchnetwork.org

 @RespirEffect

 Respiratory Effectiveness Group

 www.regresearchnetwork.org

COPYRIGHT © 2023 Respiratory Effectiveness Group



EDITORIAL

Giorgio Walter Canonica

REG President

DEAR FRIENDS AND COLLEAGUES,

I hope this newsletter finds you well and you are already enjoying a positive and fruitful start to 2023.

I am approaching the end of my first year as REG President and I look back at 2022 as a year of consolidation and a return to our normal ways of work and life. The pandemic is not officially over but we have learnt to manage with numerous measures to mitigate it, thus allowing us to re-engage in our many research projects and activities.

One of the major REG initiatives which I previously outlined, is a focus on is how to integrate the value of RWE in the current guideline procedure. We are well aware of the growing attention that has been paid to the credibility of the RWE impact. I am pleased to report that a workshop will be held next month with other scientific organisations and experts to dive into this issue and start a dialogue and engagement in addressing the process of quality evidence generation and its adoption into guidelines.

The sharing of real-life research and associated

discussions is an important platform that REG provides, so I hope that you will join us for the 2023 REG Summit, 16-18th March 2023, Lisbon, which will showcase some of the key areas of research and practice that have engaged our REG collaborators and remain hot topics as we move forward. This includes topics such as: Respiratory Infectious Challenges, New COPD Perspectives, Chronic Cough Diagnosis and Management, Childhood Respiratory Challenges, Rhinitis - United Airways Diseases, Environment and Inhaler Choice, Vaccination in Respiratory Diseases and Severe Asthma.

Please go to www.regsummit2023.org to register, to find out more and share the link with your colleagues.

I would also encourage everyone to contribute and attend the working group meetings on Thursday 16th March where new ideas for research will be discussed to hopefully provide answers to many of the questions we are faced with in our daily practice.

The REG Manifesto published in 2019 reminds us that RWE should play an important role in supporting clinical practice and better patient management. The first item REG called for and continues to advocate for is the appraisal and inclusion of high-quality real-life studies in the development of clinical practice guidelines. The journey continues.

I look forward to seeing you in Lisbon.

Giorgio Walter Canonica

Professor Respiratory Medicine - Humanitas University
Head Personalized Medicine Asthma & Allergy Clinic -
Humanitas Clinical & Research Hospital-IRCCS
Milano-Italy

REG TEAM UPDATE



Michael Walker
REG CEO

Looking back on 2022, it was a busy year for the REG team with our projects progressing well. Discussions on new ideas have developed and new projects will roll out during this year. Face to face working group meetings returned and we continue to further expand our network of collaborators and supporters.

The last few months have been focused on the preparation of the REG Summit 2023, which will be held in Lisbon from 16th - 18th March. The programme and speakers have now all been finalised and the schedule for the working group meetings on Thursday 16th March has been prepared. We hope that many of you will participate in the Summit and Working Group meetings which are open to all collaborators and supporters.

In this issue, you will find an update of the projects as well as the tremendous work of the International Severe Asthma Registry (ISAR).

I would like to acknowledge the support from a number of

long-term Sponsors. Without their ongoing support, much of the work of REG would not be possible. I hope others are encouraged and inspired by the activities of REG and the Summit in March and will collaborate with us this year or plan to in the future.

I look forward to meeting our many collaborators and supporters at the REG Summit 2023 in Lisbon.





Respiratory
Effectiveness
Group

SAVE
THE
DATE



THE RESPIRATORY
EFFECTIVENESS GROUP

REG

SUMMIT 2023

16-18 March

www.regsummit2023.org

REG SUMMIT 2023

REG looks forward to the next REG Summit. The meeting will be held in Lisbon and will bring together real-life research experts from around the world to discuss the latest findings and new areas for collaboration in their respective fields of real-life respiratory research.

The REG Summit is a well-known meeting of global respiratory key opinion leaders who actively conduct real-life research using and creating Real World Evidence. REG collaborators (researchers, clinicians, general practitioners and allied health professionals) have conducted numerous database projects as well as prospective pragmatic trials and continue to seek answers to the many complex issues faced by respiratory patients.

The REG Summit starts on Thursday 16th March with the REG Working Groups meeting to review progress on projects as well as developing new ideas and areas for further investigation. The scientific programme follows all day on Friday 17th and concludes at 13:00 on Saturday 18th March.

The scientific programme will include robust and informative discussions and debate on the latest thinking on treatment strategies and what are the needs to move the field forward to have a better understanding of how to improve patient outcomes. Participants will debate the hottest topics in the field in a variety of interactive and informative sessions.

The scientific programme will welcome an impressive list of experts who will speak about new perspectives and challenges in the management of COPD, severe asthma, chronic cough, challenging respiratory infections, the United Airways Diseases (UAD) approach to rhinitis, IPF management, vaccination in respiratory diseases, asthma in children as well as debating different treatment alternatives and strategies.

The meeting also provides an excellent opportunity for networking in-person with some of the world's leading experts in the respiratory field and to network with friends and colleagues.

The REG Summit 2023 will be the year's most important meeting in the field of respiratory real-life research, and everyone is encouraged to participate and get involved with the REG and its projects.

We look forward to seeing you in Lisbon!

ACCREDITATION



We are pleased to inform you that after evaluation the 8th REG Summit has been deemed COMPLIANT with the provisions of the MedTech Europe Code. For more information [click here](#).



Following the evaluation of the European Board for Accreditation in Pneumology (EBAP), the 8th REG Summit has been found worthy of accreditation by EBAP for 14 CME credits covering the whole program. EBAP reviewers have awarded the Mark of Excellence (MOE) for this activity which is worth an extra 4 CME credits.

WORKING GROUP MEETINGS SCHEDULE

16 March 2023

	Local Time	Geneva Room	Munich Room
THURSDAY 16 TH MARCH	12:00-13:00	NETWORKING / LUNCH	NETWORKING / LUNCH
	13:00-14:00	Technologies Working Group Ron Dandurand, <i>Canada</i>	Adherence Working Group Sinthia Bosnic-Anticevich, <i>Australia</i>
	14:00-15:00	Allergy Working Group Desiree Larenas Linnermann, <i>Mexico</i>	Database & Coding Working Group Jenni Quint, <i>United Kingdom</i>
	15:00-16:00	ILD/IPF Working Group Pilar Rivera Ortega, <i>United Kingdom</i>	COPD Working Group Marc Miravittles, <i>Spain</i>
	16:00-16:30	COFFEE BREAK	
	16:30-17:30	Cost Effectiveness Working Group Brett McQueen, <i>USA</i>	Biomarkers & Severe Asthma Working Group Leif Bjermer, <i>Sweden</i> & Zuzana Diamant, <i>The Netherlands</i>
	17:30-18:30	Environment, Epidemiology & Airways Working Group Ormar Usmani, <i>United Kingdom</i>	Child Health Working Group Clare Murray, <i>United Kingdom</i>

REG SUMMIT 2023 PRELIMINARY SCIENTIFIC PROGRAMME

17-18 March 2023

	Local Time	
FRIDAY 17 TH MARCH	08:50-09:00	Welcome G. Walter Canonica, <i>Italy</i>
	09:00-09:45	CHRONIC COUGH Chair: Alyn Morice, <i>United Kingdom</i> Diagnosis & Management of an Intractable Problem , Imran Satia, <i>Canada</i>
	09:45-10:35	RESPIRATORY INFECTIOUS CHALLENGES Chair: Nikos Papadopolous, <i>Greece</i> - New alternatives for the treatment of Bronchiectasis , Clemence Martin, <i>Paris</i> - Respiratory syncytial virus (RSV) – New perspectives in management , Sebastian Johnston, <i>United Kingdom</i>
	10:35-11:00	COFFEE BREAK
	11:00-12:30	NEW COPD PERSPECTIVES Chair: Marc Miravittles, <i>Spain</i> & Therese Lapperre, <i>Belgium</i> - PIF and Outcomes in COPD , Omar Usmani, <i>United Kingdom</i> - EARCO Registry for Alpha-1 Antitrypsin Deficiency and European Registries on COPD , Miriam Barrecheuren, <i>Spain</i> - Will Biologics Ever Have a Role in COPD? , Nicolas Roche, <i>France</i> Panel: Chin Kook Rhee, <i>South Korea</i> & Kostas Kostikas, <i>Greece</i>
	12:30-13:30	LUNCHTIME SYMPOSIUM

REG SUMMIT 2023

PRELIMINARY SCIENTIFIC PROGRAMME

17-18 March 2023

Local Time		
FRIDAY 17 TH MARCH	13:30-14:15	<p>CHILDHOOD RESPIRATORY CHALLENGES Chair: Nikos Papadopoulos, <i>Greece</i> & Clare Murray, <i>United Kingdom</i></p> <ul style="list-style-type: none"> - Quantification and Modification of the Exposome in (Pediatric) Asthma Management, Isabella Annesi-Maesano, <i>France</i> - The position of AIT in Asthma Guidelines: Where it is and Where it Could/Should Be, Désirée Larenas-Linnemann, <i>Mexico</i>
	14:15-15:00	<p>RHINITIS SESSION: UNITED AIRWAYS DISEASES Chair: Mário Morais de Almeida, <i>Portugal</i></p> <ul style="list-style-type: none"> - The United Airways Diseases (UAD) Approach, Fulvio Braido, <i>Italy</i> - New Treatment Options for the Management of Upper Airways Disease, Ignacio Ansotegui, <i>Spain</i>
	15:00-15:15	COFFEE BREAK
	15:15-16:00	<p>THE ENVIRONMENT AND INHALER CHOICE Chair: Sinthia Bosnic-Anticevich, <i>Australia</i> & Chris Carlsten, <i>Canada</i></p> <ul style="list-style-type: none"> - Climate and Inhaler Choice, Omar Usmani, <i>United Kingdom</i> - PMDI vs DPI – Does it Need to be a Choice?, Federico Lavorini, <i>Italy</i>
	16:00-16:45	<p>IN THE RESPIRATORY HOT SEAT Chair: Joan Soriano, <i>Spain</i></p> <p>Pro/Con COPD: Triple therapy should be used earlier than current guidelines recommend Pro: Kostas Kostikas, <i>Greece</i> Con: Alan Kaplan, <i>Canada</i></p>
	16:45-17:30	<p>Chair: G. Walter Canonica, <i>Italy</i></p> <p>Pro/Con ASTHMA: Biologics should be used earlier than current guidelines recommend Pro: Christian Virchow, <i>Germany</i> Con: Prof. Arnaud Bourdin</p>

Local Time		
SATURDAY 18 TH MARCH	09:00-09:30	<p>COVID-19 SESSION Chair: Dermot Ryan, <i>United Kingdom</i></p> <p>Definition and Management of Long COVID, Joan Soriano, <i>Spain</i></p>
	09:30-10:00	<p>ILD/IPF Chair: Pilar Rivera Ortega, <i>United Kingdom</i></p> <p>Management of ILD/IPF and vMDTs – Improved Patient Management?, Dr. Stefan Stanel</p>
	10:00-10:30	<p>SEVERE ASTHMA I BY ISAR</p> <ul style="list-style-type: none"> - ISAR: the year in review - ISAR research topics for the next 5 years, (results from a modified-Delphi survey) - Exploring different composite definitions of responders and non-responders to biologic treatment for severe asthma” (FULL BEAM), (results stratified by long-term OCS use)
	10:30-10:45	COFFEE BREAK

REG SUMMIT 2023

PRELIMINARY SCIENTIFIC PROGRAMME

16-18 March 2023

Local Time	
SATURDAY 18 TH MARCH	<p>SEVERE ASTHMA II BY ISAR</p> <ul style="list-style-type: none"> - Phenotypic characteristics, <i>comorbidities and responseto therapeutic interventions associated with non-type 2 asthma (EMBER) - T2-low gradient algorithm</i> - Impact of biologic initiation on new-onset OCS-related risks in patients with severe asthma (SOLAR) - preliminary results - Impact of ISAR on clinical management and outcomes, and quality improvement the way forward for integrating ISAR into clinical practice worldwide
	<p>VACCINATION IN RESPIRATORY DISEASES Chair: Filipe Froes, <i>Portugal</i></p> <ul style="list-style-type: none"> - Pneumococcal Vaccination – a Helpful Adjunct?, Alan Kaplan, <i>Canada</i> - COVID-19 Vaccination – where do we go from here?, Carlos Robalo Cordeiro, <i>Portugal</i>
	<p>RWE & GUIDELINES CONSENSUS MEETING REPORT Chair: G. Walter Canonica, <i>Italy</i></p> <ul style="list-style-type: none"> - Guidelines & RWE: Report on key points arising from workshop
	<p>13:00 Summit Close</p>

OTHER MEETINGS

Local Time		WEDNESDAY 15 TH MARCH
09:00–15:00		RWE & Guidelines Workshop

Local Time		THURSDAY 16 TH MARCH
19:30–21:30		REG Board meeting

Local Time		FRIDAY 17 TH MARCH
08:00–08:50		REG Board and WG Chairs meeting
19:00–19:30		Drinks reception
19:30–22:00		Dinner - networking

FEBRUARY 2023 WORKING GROUP UPDATE



ALLERGY WORKING GROUP

The group is developing new project ideas in the areas of allergic asthma and AIT that will be explored at the working group meeting at REG Summit in March. A study on the impact of allergic rhinitis on health-related quality of life in Australia has been completed and the manuscript is in preparation.



TECHNOLOGY WORKING GROUP

Potential new project ideas will be discussed at the working group meeting at REG Summit.



ENVIRONMENT, EPIDEMIOLOGY & AIRWAYS WORKING GROUP

The manuscript for the Inhaler Choice & Environment (ICE) project is in preparation. The project used questionnaires to identify priorities of HCPs and asthma / COPD patients in inhaler device choice and planetary health. A manuscript for the first phase of the project will be submitted shortly and the REG opinion piece will follow soon after. Visit the study website for more details: <https://www.regresearchnetwork.org/research-2/inhaler-choice-the-environment/>.



ILD WORKING GROUP

A survey aiming to characterise ILD diagnosis in the post-COVID era is now closed. There were 416 respondents from 64 countries. Analysis is now underway and an abstract for the study will be submitted to ERS Congress in February. For more information on the study, please visit the study website: <https://www.regresearchnetwork.org/research-2/global-evaluation-of-the-interstitial-lung-disease-ild-diagnostic-pathway-in-the-post-covid-era/>





COST EFFECTIVENESS WORKING GROUP

The group is developing new project ideas in cost-effectiveness of time to biologics and will have a meeting at REG Summit in March to refine the project.



ADHERENCE WORKING GROUP

The WG is finalising the preparation of two manuscripts as part of a scoping review project funded by TEVA. These are (i) investigating the adherence interventions and implications for the development of future adherence strategies (e.g., digital technologies) and (ii) assessing adherence strategies in respiratory guidelines while making recommendations for further guideline development.



CHILD HEALTH WORKING GROUP

The WG will soon start work on a new research project - "*Determining the prevalence of severe asthma in children in UK primary care*" - funded by Sanofi and led by Steve Turner. It is a retrospective epidemiological database study that will use data extracted from the Optimum Patient Care Research Database (OPCRD) to investigate the incidence of severe asthma in children by defining distinct criteria from their definition.

Paediatric Asthma in Real Life (PeARL) (PI, Nikos Papadopoulos) is an ongoing project focusing on the challenges in managing paediatric asthma. The WG has collected good results that have been used for preparing three scientific papers recently published in journals with high impact factors, and two are now under final revision.



COPD WORKING GROUP

The COPD WG is involved in distinct projects, including:

1. PIF in COPD: a prospective trial funded by BI aiming to assess the role of peak inspiratory flow (PIF) in predicting exacerbations in patients with COPD. The data on the baseline characteristics have been analysed and used for preparing the first draft of a manuscript. The study centres are continuing with patient follow-up visits and data collection.
2. PRECISE-X: the study recently approved by AstraZeneca for funding is on the development of a model for predicting the risk for first COPD severe exacerbation. Data collection and analysis will soon start.
3. Triple Therapy: the WG has developed a proposal for investigating the effects of triple pharmacological therapy on post-discharge outcomes in COPD patients and has shared this with distinct pharmaceutical companies to seek financial support.



SEVERE ASTHMA AND BIOMARKERS WORKING GROUP

During the last WG meeting in March 2022, the members defined new research ideas that are still under discussion.



DATABASES AND CODING WORKING GROUP

Last October, the WG applied for the ERS-CRC 2022 grant to establish the standardisation of respiratory definitions and outcomes using real-world data. In waiting for the announcement of the results (late February 2023), the WG has started to finalise the research idea on mapping new codes by Common Data Model (CDM), and using findings collected during the TORPEDO project and published in www.medrxiv.org/content/10.1101/2021.10.14.21264843v1.

WHAT REG MEANS TO ME

I have been involved in the REG activities since the early beginnings of this group when Marc Miravittles invited me to join the group for a meeting in Rotterdam in February 2015. At that time, I quickly realized that REG gave me a chance to network with colleagues from all over the world and join real world evidence studies that could change the care for people with respiratory diseases.

Later, I became involved in several projects within the umbrella of REG such as the COPD control studies, which resulted in many publications in respiratory journals; and the PIF study led by Omar Usmani, which is ongoing and will probably give us results in 2023. It is not only a matter of being involved in ongoing projects but also providing support for new ideas and new studies that will improve outcomes for our patients.

I have to say that REG has facilitated some questions

that I have been able to make myself during my clinical practice can be answered in a correct way, supporting me in the search for funds and in the search for contacts that can carry out the necessary tasks. An example of which is the PRECISE-X Project which will be presented at the COPD working group. In summary, if you have interests about the generation of scientific evidence in any area of respiratory medicine, I recommend that you sign up for the REG. There you will meet many leaders who will give you the necessary expert advice for your projects to be successful.

BERNARDINO ALCÁZAR NAVARRETE

Servicio de Neumología. Hospital Universitario Virgen de las Nieves, Spain



Clinical and research excellence is something we all aspire to: a continual cycle of the seeking out and application of new knowledge to improve patient outcomes. One could argue that strategy-based documents such as GINA and GOLD might cover all eventualities given their exhaustive approach to seeking out, evaluating and incorporating new evidence on a continual basis.

As a General Practitioner, I recognized long ago that such statements did not meet the needs of many of my patients, as those statements were applicable to only populations who filled criteria to be included in various clinical trials, their results collated, summated, meta-analysed and promulgated as the answer to any particular problem generally in the form of guidelines. In other words, solutions derived from clinical trials were then extrapolated back into populations which had been actively excluded from those trials without any clear vision of what their effectiveness and efficacy might be in that population.

Having recognized this, more than two decades ago, under the auspices of the Primary Care Respiratory Society (UK), money was raised to establish the first ever University chair dedicated to a specific clinical discipline in primary care at the University of Aberdeen (Professor of Primary Care Respiratory Medicine) an idea which has been replicated in other clinical disciplines. The declared intention was 'to seek primary care solutions to primary care problems' in recognition of our clinical real-life

conundrums, especially in patients with multiple co-morbidities.

REG was founded out of that philosophy and has sought to establish the consideration of evidence obtained from works which differ in concept and design from the classic double blind randomized controlled trial, providing a different sort of evidence base and one which is more permissive of identifying the right solution for the individual patient or personalised medicine, challenging the one-size fits all approach of applied by many health care systems.

I am proud of my association with this group which has managed, in a relatively short period of time, to gain acceptance of real-world evidence in the formulation of strategy documents and guidelines, at least in the respiratory world.

There remains, however, much to be done.

RYAN DERMOT

FRCGP, Honorary Clinical Research Fellow, The University of Edinburgh, Usher Institute, UK



WHAT REG MEANS TO ME

I was asked to write a personal note on this topic, which is quite close to my heart, because it always has been a bit disappointing to me to not be able to conduct a well-designed double-blind placebo-controlled trial. Due to economic reasons, it is practically impossible to survive as a sole investigator here in my country, and combining research with daily consulting to cover the economic necessities strongly reduces the time one can dedicate to research. Then, analyzing well-ranked articles especially in allergen immunotherapy, it was frequently astonishing that the reality the articles spoke of was different from our own reality. Just mentioning as an example, the major importance of house dust mites in Mexico for allergic rhinitis but even more so in allergic asthma, has only lately been given more attention; and the grass and weed pollen sensitization resulting in year-round symptoms as we have perennial polinization, be it at a lower level than the peak-pollen season in other regions; and finally the fact almost all our patients are poly-allergic, thus we consider mono-allergen AIT is not optimal.

Thus, we have always searched for a way to fuse the daily practice with clinical investigation of our reality. When a couple of years back, RWE became a concept, we embraced it and started to produce observational trials, which unfortunately are still often underrecognized in their value by journal.

Then, becoming part of the International Severe

Asthma Registry, ISAR, first and later learning about the existence of REG and its working groups and projects, a whole new world of possibilities opened to me. REG means a lot to me: from the fascinating networking with colleagues from so many regions in the world with the same interests, to the learning about the value of RWE, but also the strict quality control this kind of research has to comply with to really be of value. With ISAR, other colleagues in Mexico have become enthusiastic in participating in this global RWE project and have learnt we can generate valuable data, even within the context of our daily restrictions, and REG broadens the field further beyond asthma into other aspects of respiratory allergy. It is amazing how the group has been able to produce so many good publications till now and it is stimulating to be invited to participate in them. I am thankful for the great opportunities given and want to cooperate in developing REG further, broadening the inclusion of colleagues from Mexico and even more regions in the world.

DESIREE LARENAS LINNERMANN

MD, FAAAAI, Dist. Intl. FAAAAI
Allergist and pediatrician
Hospital Médica Sur,
Mexico City, Mexico



The Menarini Group identity is dedicated to focussing on the patient. In this regard, working in partnership with scientific societies and healthcare systems around the world, it is part of our mission to help raise the level of scientific knowledge.

The strong collaboration with HCPs from around the world, scientific societies and pharmaceutical industry provided by REG, is aligned with our aim to provide appropriate care to patients suffering from respiratory and allergic diseases. From a medical standpoint, high-level research networks, such as REG, are essential to deliver the impactful evidence we need to ensure its implementation in professional guidelines and routine care. The REG has always taken an enlightened view,

working in cooperation with the pharmaceutical industry, encouraging early involvement, and participation. We believe that the Respiratory Effectiveness Group can be an important player in providing high quality scientific data, to manage awareness and change the quality of life for respiratory and allergy patients worldwide.

ATTILIO DI GAUDIO

Global Medical Marketing Head,
Pharmaceuticals
Menarini Group



INTERNATIONAL SEVERE ISAR ASTHMA REGISTRY

◆ ISAR Country Updates

The **International Severe Asthma Registry** (ISAR) marches on into its 6th year with data from 18,120 severe asthma patients (including 16,586 patients with prospective data) from our 26 collaborating countries. We're pleased to confirm that in October 2022 we surpassed our goal to have prospective data from 13,150 patients despite the COVID-19 pandemic! We would like to thank all our collaborating countries for their valuable contributions that have made this achievement possible.

In the future, ISAR hopes to offer a new quality improvement tool that harmonizes research data collection and makes severe asthma consultations more effective globally, subject to funding beyond December 2023.

◆ ISAR Publications and Abstracts in 2022

We are pleased to share 7 ISAR publications in 2022. To view ISAR's [publications](#), [abstracts](#) and [slide sets](#), please access the [ISAR website](#).

ISAR Publications

Porsbjerg CM, et al.

"Global variability in administrative approval prescription criteria for biologic therapy in severe asthma"

J Allergy Clin Immunol Pract, 2022

Aim: To compare global differences in ease-of-access to biologics.

Conclusions: The Biologic Accessibility Score (BACS) was developed based on biologic prescription criteria; it highlighted substantial variations in ease-of-access to biologics globally.

Click [here](#) to read the full article.

Menzies-Gow AN, et al.

"Real-world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study" *J Asthma Allergy, 2022*

Aim: To describe real-life global patterns of biologic use for severe asthma, elucidate the reasons underlying these patterns, and examine patient-level factors.

Conclusions: 79% of patients with severe asthma continue treatment with their initial biologic; of the 10.8% of patients who switched, the most common first switch was from omalizumab to an Anti-IL5/5R therapy.

Click [here](#) to read the full article.

ISAR Publications

Soremekun S, et al.

"Asthma Exacerbations are Associated with a decline in Lung Function: A Longitudinal Population-Based Study" *Thorax*, 2022

Aim: To test the hypothesis that exacerbation burden is associated with age-specific, long-term lung function trajectory in asthma.

Conclusions: Asthma exacerbations were associated with faster lung function decline, which was more pronounced in younger patients.

Click [here](#) to read the full article.

Paoletti G, et al.

"Biologics in Severe Asthma: Role of Real-World Evidence from Registries" *European Respiratory Review*, 2022

Aim: To summarise the current research on real-world evidence around the use of biologics in severe asthma.

Conclusions: Registries such as ISAR provide "real-life" evidence for the effectiveness of biologics, enabling severe asthma physicians to tailor the right drugs to the right patients.

Click [here](#) to read the full article.

Chen W, et al.

"Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy" *J Asthma Allergy*, 2022

Aim: To compare the characteristics of severe asthma patients with high oral corticosteroid exposure who did and did not initiate biologics.

Conclusions: Biologic initiators were more likely to have higher blood eosinophil counts, nasal polyps, airflow limitation and uncontrolled asthma versus non-biologic initiators.

Click [here](#) to read the full article.

Price D and Uthaman T.

"What have we learnt from real-life research in asthma and COPD? Standards and novel designs for the future" *Respirology*, 2022

Aim: To highlight learnings from real-life research in asthma and COPD.

Conclusions: Real-life research has high external validity (generalizability) and can answer research questions that may be unfeasible for randomized controlled trials. Real-world evidence in asthma and COPD influences clinical guidelines and sets quality standards for patient care.

Click [here](#) to read the full article.

Pfeffer P, et al.

"Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both" *Allergy*, in press

Aim: To describe severe asthma patients eligible for both Anti-IL5/5R and Anti-IgE, and to compare the effectiveness of both biologic classes in real life.

Conclusions: In real life, both Anti-IL5/5R and Anti-IgE improve asthma outcomes; Anti-IL5/5R was more effective than Anti-IgE in reducing asthma exacerbations and long-term OCS use in patients eligible for both.

◆ ISAR Abstracts in 2022

APSR 2022

Location: Seoul, Korea

Date: 17 - 20 November 2022

Abstracts and Posters

Demographic and Clinical Characteristics of Patients with Severe Asthma in the Asian Pacific Region: data from the International Severe Asthma Registry (ISAR), Lyu J, et al.

Aim: To describe the baseline demographic and clinical characteristics of patients in the Asia-Pacific region.

Conclusions:

There is inter-country heterogeneity in the clinical characteristics of patients with severe asthma in the Asia-Pacific region, potentially because of varied access to severe asthma services and treatments.

Click [here](#) to read the full abstract.



Location: Barcelona, Spain Date: 04 - 06 September 2022

Abstracts and Posters

Effectiveness of initiating biologics in severe asthma patients with high steroid exposure (GLITTER), Chen W, et al.

Chen W, et al.

Aim: To assess comparative effectiveness of initiating versus non-initiating biologics in patients from ISAR who had high OCS exposure.

Conclusions:

Biologic initiation was associated with reduced exacerbation rate, OCS exposure and healthcare resource utilization compared to non-biologic initiation in severe asthma patients with high OCS exposure.

Click [here](#) to read the full abstract, and [here](#) for the e-Poster.

Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma (EMBER), Price D, et al.

Price D, et al.

Aim: To describe biomarker-defined clusters in severe asthma patients and characterize T2-low asthma; to compare the reductions in exacerbation rates after biologic initiation for T2-low versus other clusters.

Conclusions:

- In line with BRISAR, there was a predominantly female cluster with low biomarker levels, suggesting low T2 involvement. The other four clusters varied in biomarker elevations.
- Response to biologic initiation may be limited in the T2-low cluster.

Click [here](#) to read the full abstract, and [here](#) for the e-Poster.

Real-life biomarker response to Anti-IL5 and Anti-IgE therapies in severe asthma patients (IGNITE), Burkill S, et al.

Burkill S, et al.

Aim: To assess the proportion of patients with severe asthma whose biomarkers (BEC, FeNO and serum IgE) decrease following Anti-IL5/5R or Anti-IgE initiation.

Conclusions:

- BEC decreased to a greater extent after Anti-IL5/5R than Anti-IgE therapy.
- Both classes of biologic were associated with a moderate reduction in FeNO.
- The increase in total serum IgE observed in Anti-IgE patients suggests a complex association between Anti-IgE and partitioning of total serum IgE.

Click [here](#) to read the full abstract, and [here](#) for the e-Poster.

◆ ISAR Events in 2022



European Respiratory Society (ERS) International Conference

Barcelona, Spain

04 - 06 September 2022

SUMMARY:

- Participation of >40 collaborators from 24 countries
- ISAR GLITTER, IGNITE and EMBER posters were presented
- ISAR Research Dinner meeting
- ISAR Working Group sessions on EMBER/IGNITE, FULL BEAM and Future of ISAR




Asian Pacific Society of Respiratory (APSR) 2022

Coex, Seoul, Korea

17 - 20 November 2022

SUMMARY:

- ISAR abstract oral presentation was presented
- 3 presentations were presented at the ISAR session: Current ISAR State in Taiwan, Current ISAR State in Korea, and Current ISAR State in the World



ISAR/Singapore Severe Asthma Registry (SSAR) Launch Event

Singapore

16 September 2022

SUMMARY:

- 76 guests and attendees including local practitioners, researchers and policy makers
- Covered extensively in 5 Singapore national and regional news channels, and 3 local newspapers
- By joining the ISAR family, SSAR will actively participate in global research on severe asthma
- Click this [link](#) to access a news release of the SSAR launch event

◆ ISAR Upcoming Events in 2023



The Respiratory Effectiveness Group (REG) Summit

Lisbon, Portugal

16 - 18 March 2023

ISAR EVENTS AT REG: (to be confirmed; subject to funding)

- ISC Closed Meeting (16 March); *for ISC members only*
 - Delphi – ISAR research topics for the next 5 years
 - Future of ISAR
- ISAR Open Research Meeting (16 March); *for all ISAR collaborators*
 - Updated results from active research projects (FULL BEAM, SOLAR, STAR, IGNITE, EMBER)
 - Delphi results – ISAR research topics for the next 5 years
 - Future of ISAR
- ISC Formal Dinner (16 March); *for ISC members only*

ISAR SESSION AT REG SUMMIT: (18 March, 10:00-11:30 WET)

- ISAR BEYOND 2023. Click this [link](#) for the REG programme.
 - ISAR: the year in review
 - ISAR research topics for the next 5 years
 - FULL BEAM results stratified by long-term OCS use
 - EMBER type 2-low gradient algorithm
 - SOLAR preliminary results
 - Impact of ISAR on clinical management and outcomes, and quality improvement the way forward for integrating ISAR into clinical practice worldwide



American Thoracic Society (ATS)

Washington, DC

19 - 24 May 2023

EVENTS:

- ISAR LUMINANT and PRISM III Abstracts accepted as poster presentations to ATS 2023.



Join ISAR today!

To register interest in joining the registry as a collaborating country, please contact us [here](#).

To submit a research request or proposal for using ISAR data, please contact us [here](#).

ACKNOWLEDGEMENTS

The work of REG would not be possible without the contributions from our invaluable supporters to fund innovative research projects developed by our expert Collaborators.

REG is looking to launch a number of ambitious research initiatives that offer the opportunity to impact clinical management guidelines and patient care.

We welcome any suggestions from supporters and would be happy to discuss your ideas in more detail.

You can always get in contact with the REG team by email at enquiries@regresearchnetwork.org,

or write to Michael Walker, REG CEO at michael@regresearchnetwork.org



GOLD SUPPORTER



We would also acknowledge the support of the following companies:





Respiratory
Effectiveness
Group

THE RESPIRATORY
EFFECTIVENESS GROUP

REG

SUMMIT 2023



16 - 18
March
2023

Lisbon • **PORTUGAL**
Lisbon Marriott Hotel

www.regsummit2023.org

**SAVE
THE DATE**